Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06285539
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-02-12
Brief Title:
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Sponsor:
UMC Utrecht
Organization:
UMC Utrecht
Study Overview
Official Title:
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DRIMID
Brief Summary:
Research into novel therapies for rare immune-mediated inflammatory diseases IMIDs is limited due to small patient populations Patients with Behçets disease BD idiopathic inflammatory myopathy IIM also known as myositis and IgG4-related disease IgG4-RD are treated with high-dosed glucocorticoids methotrexate azathioprine and mycophenolate mofetil mostly for long periods of time with attendant risks of long-term toxicity including infections Therefore there is an urgent need for new more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs Due to the role of type 1 interferon in both BD IIM and IgG4-RD JAK-STAT inhibition may be a promising treatment strategy in these conditions because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None